Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2023-12-11 Regulatory Filings
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Calliditas Therapeutics received a Notice of Allowance from the USPTO for a patent application related to TARPEYO®. This announcement concerns intellectual property (IP) protection and potential future patent issuance. This topic does not fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, M&A). It is a specific regulatory/legal update regarding intellectual property rights. While it touches upon IP, it is not a formal Legal Proceedings Report (LTR) which usually covers lawsuits or regulatory actions against the company. Since it is a specific announcement about a regulatory/legal outcome (patent allowance) that is not covered by the other specific codes, the most appropriate classification is the general Regulatory Filings category (RNS), as it is a formal announcement of a regulatory event. Alternatively, given the focus on patent protection, it could be argued as a type of Investor Information, but RNS serves as the best catch-all for specific, non-standard regulatory updates.
2023-12-11 English
Calliditas announces additions to the management team
Board/Management Information Classification · 100% confidence The document is a press release dated December 1, 2023, announcing specific personnel changes: the addition of a new Head of Technical Operations and a new Group General Counsel, along with the retirement of the previous General Counsel. This content directly relates to changes in the company's senior leadership and board structure. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is not a full financial report (10-K, IR), an earnings release (ER), or a presentation (IP). Therefore, MANG is the most appropriate classification.
2023-12-01 English
Calliditas utökar ledningsgruppen
Board/Management Information Classification · 100% confidence The document is a press release announcing changes in the company's senior management team (hiring a new Head of Technical Operations and a new Group General Counsel). This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-12-01 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January to September 2023. It contains comprehensive financial statements, including income statements, balance sheet data, cash flow analysis, and detailed management commentary on business performance, clinical trial results, and future outlook. It is clearly a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. 9M 2023
2023-11-07 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – SEPTEMBER 2023' and contains comprehensive financial statements, including net sales, operating loss, earnings per share, and cash flow data for the specified period. It also includes a CEO statement, pipeline updates, and key figures tables. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2023
2023-11-07 English
Calliditas Therapeutics valberedning utsedd inför årsstämma 2024
AGM Information Classification · 95% confidence The document is a short announcement dated October 23, 2023, titled 'Calliditas Therapeutics valberedning utsedd inför årsstämma 2024' (Calliditas Therapeutics Nomination Committee appointed ahead of the Annual General Meeting 2024). It details the composition of the Nomination Committee responsible for proposing board members and auditors for the upcoming 2024 AGM. This content directly relates to the governance and preparation for the Annual General Meeting (AGM). While it is not the AGM presentation itself (AGM-R), it is a specific announcement regarding the governance structure leading up to the AGM, which falls under Governance Information (CGR) or potentially a specific aspect of AGM preparation. However, given the specific focus on the 'valberedning' (Nomination Committee) which is a key governance body, CGR is a strong fit. Since the document is short and announces a specific governance action related to the AGM, and CGR covers 'internal rules, board structure, and governance practices,' this classification is appropriate. It is not a DEF 14A (Remuneration) or DVA (Voting Results).
2023-10-23 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.